石四藥(02005.HK)多款產品獲納入疫情防護家庭常備藥品目錄
石四藥集團(02005.HK)公布,上海及武漢有關部門近日制定「止咳、退熱、抗病毒、抗菌素」四類藥品目錄,涉及共174款藥品,而集團旗下抗病毒藥物鹽酸阿比多爾膠囊,抗菌藥阿奇黴素分散片、阿奇黴素乾混懸劑、阿奇黴素片、頭孢地尼膠囊、頭孢克洛乾混懸劑,中成藥銀黃膠囊等多款產品,被納入今次的疫情防護家庭常備藥品目錄當中。
集團表示,研究顯示阿比多爾對治療Omicron變異病毒株安全有效,作為門急診口服給藥方便經濟。阿比多爾可有效改善低淋巴細胞血症,在抗病毒過程中具有免疫調節作用。
石藥阿比多爾於2006年獲批上市,獲批適應症為甲型、乙型流感病毒引起的上呼吸道感染。目前國內抗疫新形勢下,需求量猛增,處於供不應求狀態,集團是中國最大的阿比多爾原料藥和膠囊製劑生產商,及國內阿奇黴素原料藥和各類製劑的重要生產商,預期阿比多爾和阿奇黴素將為集團帶來突破性增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.